抗风湿治疗对亚洲类风湿关节炎患者心血管风险的影响
该回顾性队列研究基于韩国国民健康保险索赔数据库,纳入137,512例类风湿关节炎(RA)患者,评估心血管疾病(CVD)发生率及抗风湿治疗的影响。结果显示CVD总发生率为182.1/10,000人年(95%CI: 178.4-185.9);调整混杂因素后,改善病情抗风湿药(DMARDs)对CVD具有保护作用(OR=0.79),而糖皮质激素(OR=1.26)和非甾体抗炎药(NSAIDs)增加CVD风险。
要点
- 亚洲RA患者CVD发生率为182.1/10,000人年。
- DMARDs使用与CVD风险降低相关(OR=0.79)。
- 糖皮质激素及NSAIDs与CVD风险升高相关。
核心结论
- DMARDs对RA患者CVD具有保护作用,而糖皮质激素和NSAIDs增加CVD风险。
研究设计与样本
- 基于韩国国民健康保险索赔数据库(2009年1月至2013年12月)的回顾性队列研究,共识别137,512例RA患者。
- 采用巢式病例对照设计,按1:4匹配,纳入7,102例CVD病例和27,018例无CVD对照。
- 使用条件多变量回归模型评估抗风湿治疗对CVD的影响,匹配年龄、性别、RA索引日期、合并症及药物使用。
主要发现
- RA患者总体CVD发生率为182.1/10,000人年(95%CI: 178.4-185.9)。
- 调整其他CVD风险因素后,DMARDs与CVD风险降低相关(OR=0.79)。
- 生物制剂DMARDs与CVD风险无显著关联(OR=0.85)。
- 糖皮质激素与CVD风险升高相关(OR=1.26)。
- 非选择性NSAIDs(OR=1.32)和Cox-2抑制剂(OR=1.31)与CVD风险升高相关。
临床怎么用
- 在RA治疗中应考虑DMARDs对心血管的保护作用,并谨慎使用糖皮质激素和NSAIDs以降低CVD风险。
局限性
- 本研究为回顾性队列研究,基于索赔数据库,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the incidence of cardiovascular disease (CVD) in Asian patients with rheumatoid arthritis (RA) and to evaluate the impact of anti-rheumatic treatment on the development of CVD. METHODS: A retrospective cohort of Asian patients with RA was established to identify the incidence rate (IR) of CVD in RA patients. The cohort was generated using the Korean National Healthcare claims database, which contained claims from Jan 2009 to Dec 2013. A total of 137,512 RA patients were identified; individuals with a history of CVD for 6 months or more before the index date were excluded. Nested case-control samples were drawn from the full study population with a case:control ratio of 1:4 (n = 7102 cases; n = 27,018 controls without CVD). A conditional multivariate regression model was used to evaluate the impact of anti-rheumatic treatment on the development of CVD in RA patients after matching for age, sex, RA index date, comorbidities, and drug use (e.g., antiplatelet agents and cholesterol-lowering agents). RESULTS: The IR for development of overall CVD in RA patients was 182.1 (95% CI: 178.4-185.9) per 10,000 person-years. In models adjusted for other CVD risk factors, disease-modifying anti-rheumatic drugs (DMARDs) (OR = 0.79) were protective against CVD, and biologic DMARDs were not significantly associated with CVD risk (OR = 0.85). Corticosteroids (OR = 1.26) and NSAIDs (nonselective NSAIDs: OR = 1.32, Cox-2 inhibitors: OR = 1.31) were risk factors for CVD in RA patients. CONCLUSIONS: The use of DMARDs is protective against CVD, while corticosteroids and NSAIDs increased the risk of CVD in RA patients.
引用
- Cho SK, Kim D, Won S, et al. Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis. Semin Arthritis Rheum. 2017. PMID: 28863826. doi:10.1016/j.semarthrit.2017.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。